Pfizer Inc. (PFE) is a Healthcare stock trading at $25.05 (as of 2026-07-17), with a market capitalization of $142.77B and a trailing P/E of 19.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer discovers, develops, manufactures, and sells biopharmaceutical medicines and vaccines worldwide, and it makes money by marketing and distributing branded therapies across therapeutic areas (for example Eliquis, Ibrance, Xtandi, Premarin) and by selling products including sterile injectables, anti-infectives, and COVID-19 treatments and vaccines such as Paxlovid and Comirnaty.
Pfizer’s profit model is driven by the mix of ongoing non-COVID-19 product revenues plus separately reported COVID-19 portfolio revenues (including Comirnaty and Paxlovid), with results influenced by COVID-19 demand and items such as Paxlovid U.S. government contract return adjustments.
Business quality (Mixed): The available operating indicators are focused on product-level revenue drivers (non-COVID-19 product revenues, Paxlovid, Comirnaty, and COVID-19 portfolio revenues). However, a clean official reportable segment breakdown is not provided here, so the view is best thought of as a product mix map rather than a full segment accounting picture.
Valuation: At 19× earnings, PFE trades 10% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $25.05 |
| Market Cap | $142.77B |
| P/E Ratio | 19.1 |
| EV / EBITDA | 14.2 |
| Price / Book | 1.58 |
| Price / Sales | 2.25 |
| FCF Yield | 6.6% |
| DCF Value (model) | $22.49 |
| DCF Upside vs Price | -10.2% |
| Revenue (TTM) | $62.58B |
| Net Margin | 12.4% |
| Revenue Growth (YoY) | 5.4% |
| EPS Growth (YoY) | -9.6% |
| FCF Growth (YoY) | 23.0% |
| Altman Z-Score | 1.93 (grey) |
| Piotroski F-Score | 5/9 (moderate) |
| Stock P/E | 19.1 |
| Sector P/E (Healthcare) | 21.4 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -11.1% |
| vs Industry | 12.3% |
| Top Institutional Holder | BlackRock, Inc. ($13.99B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Albert Bourla |
| Employees | 81,000 |
| Country | US |
| IPO Date | 1972-06-01 |
Data as of 2026-07-17.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.